Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2

Conditions

Breast Neoplasms 41Carcinoma, Renal Cell 31Neoplasms 18Kidney Neoplasms 17Neuroendocrine Tumors 16Neoplasm Metastasis 13Tuberous Sclerosis 10Prostatic Neoplasms 8Carcinoma 8Lymphoma, Mantle-Cell 7Lymphoma, Large B-Cell, Diffuse 7Hodgkin Disease 7Glioma 7Glioblastoma 7Astrocytoma 7Waldenstrom Macroglobulinemia 6Triple Negative Breast Neoplasms 6Recurrence 6Lymphoma 6Head and Neck Neoplasms 6Stomach Neoplasms 5Ovarian Neoplasms 5Colorectal Neoplasms 5Carcinoma, Neuroendocrine 5Brain Neoplasms 5Sezary Syndrome 4Sarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Pancreatic Neoplasms 4Mycosis Fungoides 4

Interventions

antineoplaston AS 2-1 3antineoplaston A10 3dactolisib 2Temozolomide 2Irinotecan 2Everolimus 2Bevacizumab 2surufatinib 1spartalizumab 1poly ICLC 1plerixafor 1pasireotide 1fosbretabulin 1cixutumumab 1adavosertib 1Vaccines 1TH 302 1Sunitinib 1Radiotherapy, Image-Guided 1Radiotherapy 1Radiation 1PM 00104 1Lapatinib 1Immunologic Techniques 1Immunoglobulin G 1Genistein 1Fentanyl 1Donepezil 1Disulfides 1Decitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Neuroectodermal Tumors, Primitive × Everolimus × Clear all
NCT01374451 2016-12-20

COOPERATE-2

Novartis

Phase 2 Terminated
160 enrolled 17 charts
EndocrineNET

Adenoma, Islet Cell, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT01628913 2016-04-07

Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

Novartis

Phase 2 Terminated
62 enrolled 7 charts
EndocrineNET

Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡